HER2-Negative Breast Cancer Global Market Report 2025

Description

HER2-negative breast cancer is a type of breast cancer in which the cancer cells do not overexpress the HER2 protein, which is responsible for promoting tumor growth. This form of cancer generally grows more slowly than HER2-positive breast cancer and is treated using targeted therapies and chemotherapy.

The primary treatment options for HER2-negative breast cancer include chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of powerful drugs to destroy or inhibit the growth of cancer cells by targeting rapidly dividing cells in the body. Treatment is administered at various stages, including the early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The HER2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides HER2-negative breast cancer market statistics, including HER2-negative breast cancer industry global market size, regional shares, competitors with HER2-negative breast cancer market share, detailed HER2-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the HER2-negative breast cancer industry. This HER2-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The her2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to the rise in breast cancer cases, increased awareness about breast cancer, increased spending on healthcare, an aging population, and expanding healthcare infrastructures.

The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing consumption of alcohol, increasing adoption of unhealthy lifestyles, increasing prevalence of obesity, increasing consumption of tobacco, and increasing need for effective treatment solutions. Major trends in the forecast period include innovations in diagnostic technologies, integration of targeted therapies, integration of immunotherapies, FDA approvals, and technological advancements.

The forecast of 7.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of CDK4/6 inhibitors (e.g., palbociclib) and PARP inhibitors sourced from the UK and Singapore, thereby delaying metastatic disease control and elevating oncology pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of breast cancer is expected to drive the growth of the HER2-negative breast cancer market. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, typically originating in the ducts or lobules. Several factors contribute to the rising number of breast cancer cases, including heightened awareness and advancements in screening technologies, which lead to earlier and more frequent detection. HER2-negative breast cancer research is critical in understanding distinct tumor biology and developing targeted therapies that improve treatment outcomes. For example, in June 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that in 2021, 272,454 new cases of breast cancer were diagnosed among females in the United States, with 42,211 deaths recorded in 2022. This growing prevalence underscores the increasing demand for effective HER2-negative breast cancer treatments.

Leading companies in the HER2-negative breast cancer market are actively pursuing regulatory approvals to introduce new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals represent official authorizations granted by government agencies, ensuring that drugs and treatments meet safety, efficacy, and quality standards before commercialization. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be administered in combination with palbociclib and fulvestrant, significantly enhancing progression-free survival compared to standard treatments. The newly approved regimen offers a crucial treatment option for patients with limited alternatives, highlighting the importance of biomarker testing in identifying those most likely to benefit from the therapy.

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, partnered with Pfizer Inc. to evaluate the combination of atirimociclib, Pfizer's investigational selective CDK4 inhibitor, with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration seeks to leverage the distinct properties of both drugs to minimize off-target toxicity, which has historically limited the effectiveness of non-selective agents. Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, continues to play a key role in the development of innovative treatments for HER2-negative breast cancer.

Major players in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in HER2-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the HER2-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2-Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2-negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2-negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The her2-negative breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy
2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company; Sanofi S.A.; AstraZeneca PLC; Novartis International AG; Eli Lilly and Company; Amgen Inc.; Daiichi Sankyo Company Limited; Jiangsu Hansoh Pharmaceutical Co. Ltd.; BeiGene Ltd.; Chipscreen Biosciences Ltd.; F. Hoffmann-La Roche Ltd; PharmAbcine Inc.; Adagene Inc.; H3 Biomedicine Inc.; Radius Health Inc.; Zenith Epigenetics Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34069u

1. Executive Summary

2. HER2-Negative Breast Cancer Market Characteristics

3. HER2-Negative Breast Cancer Market Trends And Strategies

4. HER2-Negative Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global HER2-Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global HER2-Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global HER2-Negative Breast Cancer Market Growth Rate Analysis
5.4. Global HER2-Negative Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global HER2-Negative Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global HER2-Negative Breast Cancer Total Addressable Market (TAM)

6. HER2-Negative Breast Cancer Market Segmentation

6.1. Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Hormone Therapy
Targeted Therapy
Immunotherapy
6.2. Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Locally Advanced Stage
Metastatic Stage
6.3. Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anthracyclines
Taxanes
Platinum-Based Chemotherapy
Alkylating Agents
Antimetabolites
6.5. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Selective Estrogen Receptor Degraders (SERDs)
6.6. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
CDK4/6 Inhibitors
PI3K Inhibitors
PARP Inhibitors
6.7. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Tumor-Infiltrating Lymphocyte (TIL) Therapy

7. HER2-Negative Breast Cancer Market Regional And Country Analysis

7.1. Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Negative Breast Cancer Market

8.1. Asia-Pacific HER2-Negative Breast Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Negative Breast Cancer Market

9.1. China HER2-Negative Breast Cancer Market Overview
9.2. China HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Negative Breast Cancer Market

10.1. India HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Negative Breast Cancer Market

11.1. Japan HER2-Negative Breast Cancer Market Overview
11.2. Japan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Negative Breast Cancer Market

12.1. Australia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Negative Breast Cancer Market

13.1. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Negative Breast Cancer Market

14.1. South Korea HER2-Negative Breast Cancer Market Overview
14.2. South Korea HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Negative Breast Cancer Market

15.1. Western Europe HER2-Negative Breast Cancer Market Overview
15.2. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Negative Breast Cancer Market

16.1. UK HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Negative Breast Cancer Market

17.1. Germany HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Negative Breast Cancer Market

18.1. France HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Negative Breast Cancer Market

19.1. Italy HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Negative Breast Cancer Market

20.1. Spain HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Negative Breast Cancer Market

21.1. Eastern Europe HER2-Negative Breast Cancer Market Overview
21.2. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Negative Breast Cancer Market

22.1. Russia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Negative Breast Cancer Market

23.1. North America HER2-Negative Breast Cancer Market Overview
23.2. North America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Negative Breast Cancer Market

24.1. USA HER2-Negative Breast Cancer Market Overview
24.2. USA HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Negative Breast Cancer Market

25.1. Canada HER2-Negative Breast Cancer Market Overview
25.2. Canada HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Negative Breast Cancer Market

26.1. South America HER2-Negative Breast Cancer Market Overview
26.2. South America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Negative Breast Cancer Market

27.1. Brazil HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Negative Breast Cancer Market

28.1. Middle East HER2-Negative Breast Cancer Market Overview
28.2. Middle East HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Negative Breast Cancer Market

29.1. Africa HER2-Negative Breast Cancer Market Overview
29.2. Africa HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles

30.1. HER2-Negative Breast Cancer Market Competitive Landscape
30.2. HER2-Negative Breast Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Negative Breast Cancer Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. AstraZeneca PLC
31.3. Novartis International AG
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Daiichi Sankyo Company Limited
31.7. Jiangsu Hansoh Pharmaceutical Co. Ltd.
31.8. BeiGene Ltd.
31.9. Chipscreen Biosciences Ltd.
31.10. F. Hoffmann-La Roche Ltd
31.11. PharmAbcine Inc.
31.12. Adagene Inc.
31.13. H3 Biomedicine Inc.
31.14. Radius Health Inc.
31.15. Zenith Epigenetics Ltd.

32. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market

34. Recent Developments In The HER2-Negative Breast Cancer Market

35. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies

35.1 HER2-Negative Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 HER2-Negative Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 HER2-Negative Breast Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer